Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Creemers JHA, van der Doelen MJ, van Wilpe S, Hermsen R, Duiveman-de Boer T, Somford DM, Janssen MJR, Sedelaar JPM, Mehra N, Textor J, Westdorp H. Creemers JHA, et al. Among authors: hermsen r. Front Oncol. 2021 May 18;11:667658. doi: 10.3389/fonc.2021.667658. eCollection 2021. Front Oncol. 2021. PMID: 34084750 Free PMC article.
Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
Baas DJH, Schilham M, Hermsen R, de Baaij JMS, Vrijhof HJEJ, Hoekstra RJ, Sedelaar JPM, Küsters-Vandevelde HVN, Gotthardt M, Wijers CHW, van Basten JP, Somford DM. Baas DJH, et al. Among authors: hermsen r. Prostate Cancer Prostatic Dis. 2022 Mar;25(1):65-70. doi: 10.1038/s41391-021-00452-y. Epub 2021 Sep 1. Prostate Cancer Prostatic Dis. 2022. PMID: 34471231
Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
Hermsen R, Wedick EBC, Vinken MJM, van Kalmthout LWM, Küsters-Vandevelde HVN, Wijers CHW, Somford DM, van Basten JA. Hermsen R, et al. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3929-3937. doi: 10.1007/s00259-022-05827-4. Epub 2022 May 11. Eur J Nucl Med Mol Imaging. 2022. PMID: 35543733 Clinical Trial.
Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia's Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80.
Schilham MGM, Rijpkema M, Scheenen T, Hermsen R, Barentsz JO, Sedelaar JPM, Kusters-Vandevelde H, Kerkmeijer LGW, Somford DM, Gotthardt M. Schilham MGM, et al. Among authors: hermsen r. Eur Urol. 2023 May;83(5):e133-e134. doi: 10.1016/j.eururo.2023.01.023. Epub 2023 Feb 11. Eur Urol. 2023. PMID: 36781337 No abstract available.
Head-to-Head Comparison of 18F-PSMA-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Whole-mount Histopathology as Reference in Localisation and Staging of Primary Prostate Cancer.
Exterkate L, Hermsen R, Küsters-Vandevelde HVN, Prette JF, Baas DJH, Somford DM, van Basten JA. Exterkate L, et al. Among authors: hermsen r. Eur Urol Oncol. 2023 Dec;6(6):574-581. doi: 10.1016/j.euo.2023.04.006. Epub 2023 May 23. Eur Urol Oncol. 2023. PMID: 37230883
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702 Free article.
Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.
Schilham MGM, Somford DM, Küsters-Vandevelde HVN, Hermsen R, van Basten JPA, Hoekstra RJ, Scheenen TWJ, Gotthardt M, Sedelaar JPM, Rijpkema M. Schilham MGM, et al. Among authors: hermsen r. J Nucl Med. 2024 Mar 1;65(3):423-429. doi: 10.2967/jnumed.123.266495. J Nucl Med. 2024. PMID: 38176721 Clinical Trial.
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Bosch D, van der Velden KJM, Oving IM, Wyndaele DNJ, Weijs LE, van Schelven WD, Oyen WJG, Te Beek ET, van de Luijtgaarden ACM, Somford DM, Nagarajah J, Hermsen R, Mehra N, Gerritsen WR, van der Doelen MJ, van Oort IM. Bosch D, et al. Among authors: hermsen r. J Nucl Med. 2024 Apr 1;65(4):541-547. doi: 10.2967/jnumed.123.266654. J Nucl Med. 2024. PMID: 38423781
84 results